An exploratory phase II clinical trial of apatinib in progressive radioiodine refractory differentiated thyroid cancer

被引：1
|
作者：
Lin, Yan-Song [1 ]
Zhang, Xin [1 ]
Liu, Yanqing [1 ]
Wang, Chen [1 ]
Zhang, Teng [1 ]
机构：
[1] Peking Union Med Coll Hosp, Dept Nucl Med, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e18094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18094
引用
收藏
页数：2
相关论文
共 50 条
  • [41] THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Huang, W.
    Chen, L.
    Ting, J.
    Cao, V
    Sung, H.
    Yokokura, M.
    Wilson, L.
    VALUE IN HEALTH, 2016, 19 (07) : A886 - A886
  • [42] Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective
    Fabian Pitoia
    Rafael Selbach Scheffel
    Ines Califano
    Alicia Gauna
    Hernán Tala
    Fernanda Vaisman
    Alejandro Roman Gonzalez
    Ana Oliveira Hoff
    Ana Luiza Maia
    Reviews in Endocrine and Metabolic Disorders, 2024, 25 : 109 - 121
  • [43] Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective
    Pitoia, Fabian
    Scheffel, Rafael Selbach
    Califano, Ines
    Gauna, Alicia
    Tala, Hernan
    Vaisman, Fernanda
    Gonzalez, Alejandro Roman
    Hoff, Ana Oliveira
    Maia, Ana Luiza
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2024, 25 (01): : 109 - 121
  • [44] Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients
    Saie, C.
    Wassermann, J.
    Mathy, E.
    Chereau, N.
    Leenhardt, L.
    du Montcel, S. Tezenas
    Buffet, C.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 184 (05) : 667 - 676
  • [45] A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer - Discussion
    Grant, Clive
    Kebebew, Electron
    Dackiw, Alan P. B.
    Patel, Subhash
    SURGERY, 2006, 140 (06) : 966 - 967
  • [46] A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting
    Brose, Marcia S.
    Shenoy, Sangeeta
    Bhat, Nikhil
    Harlacker, Anne K.
    Yurtal, Raven K.
    Posey, Zakkiyya A.
    Torrente, Dena M.
    Grande, Carolyn
    Squillante, Christian Michael
    Troxel, Andrea
    Yarchoan, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
    Shen, Huize
    Zhu, Rui
    Liu, Yanyang
    Hong, Yangjian
    Ge, Jiaming
    Xuan, Jie
    Niu, Wenyuan
    Yu, Xuefei
    Qin, Jiang-Jiang
    Li, Qinglin
    DRUG RESISTANCE UPDATES, 2024, 72
  • [48] Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
    Herranz, Urbano Anido
    CANCER MEDICINE, 2022, 11 : 47 - 53
  • [49] Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
    Bible, Keith C.
    Suman, Vera J.
    Molina, Julian R.
    Smallridge, Robert C.
    Maples, William J.
    Menefee, Michael E.
    Rubin, Joseph
    Sideras, Kostandinos
    Morris, John C., III
    McIver, Bryan
    Burton, Jill K.
    Webster, Kevin P.
    Bieber, Carolyn
    Traynor, Anne M.
    Flynn, Patrick J.
    Goh, Boon Cher
    Tang, Hui
    Ivy, Susan Percy
    Erlichman, Charles
    LANCET ONCOLOGY, 2010, 11 (10): : 962 - 972
  • [50] Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas
    Ain, Kenneth B.
    Lee, Charles
    Williams, Kevin D.
    THYROID, 2007, 17 (07) : 663 - 670
12345